Chemokine Therapeutics, PPD deal

CTI reacquired rights to its CTCE-0214 from PPDI. The small peptide agonist of chemokine CXC motif ligand 12 (CXCL12) (SDF-1) is in a Phase Ib trial to mobilize stem cells and neutrophils. PPDI will ...